Pharma and biotech M&A is set to slow globally in 2016

After a feverish 2015, a convergence of factors may cool M&A activity in the sector this year

You must be signed in to read this analysis

Sign in Sign up to our newsletter

What is this?

This summary is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.

This summary refers to the following article(s).